Author; Journal, year (Trial name) | Line | Design | n | ORR (%) | CBR (%) |
---|---|---|---|---|---|
Lϕnning; J Clin Oncol, 2000 [9] | 2nd ~ 4th | nsAI → EXE | 105 | 4.8 | 20.0 |
Iaffaioli; Br J Cancer, 2005 [10] | 2nd ~ 3rd | ANA → EXE | 50 | 8.0 | 44.0 |
Steele; Breast, 2005 [4] | 2nd~ > 4th | nsAI → EXE | 114 | 5.0 | 46.0 |
Thürlimann; Eur J Cancer, 2003 [13] | 2nd | ANA → TAM | 119 | 10.1 | 48.7 |
Chia; J Clin Oncol, 2008 (EFECT) [12] | 2nd~ > 4th | nsAI → FUL loading dose | 270 | 7.4 | 32.2 |
nsAI → EXE | 270 | 6.7 | 31.5 | ||
Yamamoto; Breast Cancer, 2010 (Hi-FAIR) [8] | 2nd~ > 4th | AIs → TOR120 | 80 | 15.0 | 45.0 |
Di Leo; J Clin Oncol, 2010 [14] | 2nd | AI or SERM → FUL500 | 362 | 9.1 | 45.6 |
AI or SERM → FUL250 | 374 | 10.2 | 39.6 | ||
Bachelot T: J Clin Oncol. 2012 (TAMRAD) [17] | 2nd~ > 4th | nsAI → TAM | 57 | 13.0 | 42.1 |
nsAI → TAM + RAD001 | 54 | 14.0 | 61.1 | ||
Baselga; N Engl J Med, 2012 (Bolero2) [16] | 2nd ~ 4th | nsAI → EXE | 239 | 0.4 | 18.0 |
nsAI → EXE + RAD001 | 484 | 9.5 | 33.4 |